Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neuraptive Therapeutics

Request full access

Bringing novel therapeutic technology for the acute surgical repair of injured peripheral nerves

Tredyffrin Township, United StatesFounded 2016Biotech & Life Sciences

About Neuraptive Therapeutics

Neuraptive Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for peripheral nerve injuries. The company operates in the pharmaceutical and medical device market, targeting healthcare providers and patients who suffer from nerve damage. Neuraptive's business model revolves around research and development (R&D) of novel treatments, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, including sales and potential licensing agreements. The company leverages its experienced leadership team, with extensive backgrounds in biotech and pharmaceutical industries, to navigate the complex landscape of drug development and regulatory compliance. Neuraptive is headquartered in Philadelphia, with additional operations in Colorado.

Source: Dealroom company data

At a glance

Status
Operational
Employees
13
Open positions
None listed
Dealroom signal
38.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Oct 2022 $38M $153M Undisclosed ↗
SERIES AOther financing Dec 2018 $12M $46M New Rhein Healthcare ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Neuraptive Therapeutics website traffic

Latest recorded traffic for Neuraptive Therapeutics is 2K monthly website visits, up 17.6% over the last three months. Neuraptive Therapeutics's team declined 13.3% over the past year.

Latest monthly visits2K 3-month web change+17.6% 1-year team growth-13.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
ProJenXProJenX is a clinical-stage biotechnology company with novel, brain-penetrant targeted therapies to address debilitating brain diseases, with an initial focus on ALS New York City, United States Operational 9 $21M $60M
Teitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases Aarhus, Denmark Operational
Harness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs Babraham, United Kingdom Operational
Orbit HealthHarnessing sensors and AI, enables effective early intervention and personalized care for chronic diseases Berlin, Germany Operational
ElectroCoreHelping patients across the globe who suffer from pain and chronic conditions by harnessing the power of nVNS, innovation, and technology to develop safe and clinically backed treatments Rockaway Township, United States Operational
Zhimeng BiopharmaDiscovering and developing the most effective, safe and affordable drugs to improve the quality of life of patients in China and abroad Huangpu, China Operational
AstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases Reading, United Kingdom Operational
EncefaDevelops biologics that specifically modulate a key age-related target, to fight neurodegenerative, auto-immune, and more broadly age-related diseases Paris, France Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Neuraptive Therapeutics in the Tredyffrin Township ecosystem

Live from Dealroom

The Neuraptive Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Central Texas Angel Network
  • New Rhein Healthcare
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States90%
🇦🇺 Australia10%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neuraptive Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neuraptive Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.